Supernus Pharmaceuticals, Inc. (SUPN) Holdings Cut by Castleark Management LLC

Castleark Management LLC decreased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 20.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 223,350 shares of the specialty pharmaceutical company’s stock after selling 57,741 shares during the period. Castleark Management LLC owned approximately 0.44% of Supernus Pharmaceuticals worth $9,626,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Meeder Asset Management Inc. increased its position in Supernus Pharmaceuticals by 3,455.2% during the 2nd quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock worth $103,000 after purchasing an additional 2,315 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Supernus Pharmaceuticals by 278.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock worth $130,000 after purchasing an additional 2,220 shares during the period. Riverhead Capital Management LLC increased its position in Supernus Pharmaceuticals by 91.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 1,462 shares during the period. Advisor Group Inc. increased its position in Supernus Pharmaceuticals by 13.7% during the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after purchasing an additional 410 shares during the period. Finally, Victory Capital Management Inc. increased its position in Supernus Pharmaceuticals by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after purchasing an additional 517 shares during the period. Institutional investors own 95.36% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.truebluetribune.com/2017/10/13/supernus-pharmaceuticals-inc-supn-holdings-cut-by-castleark-management-llc.html.

SUPN has been the topic of a number of research reports. Cantor Fitzgerald upped their price target on Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a “buy” rating in a report on Wednesday, July 5th. Stifel Nicolaus cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 price target on the stock. in a report on Tuesday, September 19th. They noted that the move was a valuation call. Cowen and Company restated a “positive” rating and issued a $50.00 price target (up previously from $40.00) on shares of Supernus Pharmaceuticals in a report on Thursday, August 3rd. BidaskClub cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and issued a $45.00 target price on shares of Supernus Pharmaceuticals in a research note on Friday, September 8th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $47.71.

In related news, CFO Gregory S. Patrick sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction on Friday, September 8th. The shares were sold at an average price of $47.60, for a total value of $2,380,000.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Stefan K.F. Schwabe sold 95,000 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $46.59, for a total transaction of $4,426,050.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 153,709 shares of company stock valued at $7,223,108. 6.70% of the stock is owned by company insiders.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The business had revenue of $75.83 million during the quarter, compared to analyst estimates of $68.54 million.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply